Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes

Shira Hirsch, Liad Hinden, Meital Ben David Naim, Saja Baraghithy, Anna Permyakova, Shahar Azar, Taher Nasser, Emma Portnoy, Majd Agbaria, Alina Nemirovski, Gershon Golomb, Joseph Tam*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science